FDA approves deadly drug … even after debating its ‘effectiveness’
10/10/2016 // JD Heyes // Views

It is often difficult to understand why government bureaucracies do some of the things they do, and obviously that includes the Food and Drug Administration, the agency responsible for approving some of the most dangerous drugs ever marketed.

In fact, the agency may just have done so again.

As reported by medical website STAT, the FDA’s chief, Dr. Robert Califf, wants a study about a Duchenne muscular dystrophy drug called eteplirsen retracted because he believes it was misleading. The problem is, the drug has already been approved.

Developed by Sarepta Therapeutics, the drug is the first to be approved for the rare genetic disease which leads to a steady erosion and wasting of muscles that eventually consigns boys to wheelchairs and an early grave. STAT reports that Duchenne was approved in spite of often rancorous disagreement out of the limelight among top FDA officials regarding the extent that the drug actually helps patients.

Central to the infighting was a 2013 study into whether the drug was able to produce levels of a protein called dystrophin in sufficient amounts. Without that protein, muscle fibers deteriorate and voluntary movement disappears.

The study, which of course was funded by the drug maker and co-authored by four of the pharmaceutical’s employees, found that the medicine produced enough dystrophin and allowed affected boys some ability to walk.

But Califf sided with a pair of FDA officials who also believe that the study, which was published in the journal Annals of Neurology, should be pulled.


“The publication, now known to be misleading, should probably be retracted by its authors,” Califf wrote in a memo, in which he touched on the internal dispute within his agency.

“In view of the scientific deficiencies identified in this analysis, I believe it would be appropriate to initiate a dialogue that would lead to a formal correction or retraction (as appropriate) of the published report,” the agency chief added in a footnote.

The disagreement was initiated in large part by various moves made by Dr. Janet Woodcock, the controversial manager of the FDA’s drug review division, who pushed hard for the approval of the Sarepta drug.

Though she reportedly had concerns about the study, she also argued with other agency officials who did not agree with her decision to approve the drug, as well the manner in which she advocated on behalf of the drug’s approval.

The trouble is, it’s unclear where the situation goes from here. Dr. Clifford Saper, editor of the Annals of Neurology, said that getting a paper retracted is no quick or easy thing.

“It takes more than a call by a politician for retraction of a paper. It takes actual evidence,” he told STAT. He added that if Califf has evidence that there are errors in the paper, he should produce it.

Meanwhile, another drug that is likely ineffective and perhaps even expensive will be permitted to remain on the market and in use.



FDA.gov [PDF]

Take Action:
Support Natural News by linking to this article from your website.
Permalink to this article:
Embed article link:
Reprinting this article:
Non-commercial use is permitted with credit to NaturalNews.com (including a clickable link).
Please contact us for more information.
Free Email Alerts
Get independent news alerts on natural cures, food lab tests, cannabis medicine, science, robotics, drones, privacy and more.
App Store
Android App
eTrust Pro Certified

This site is part of the Natural News Network © 2022 All Rights Reserved. Privacy | Terms All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing International, LTD. is not responsible for content written by contributing authors. The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. Truth Publishing assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms and those published here. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.

This site uses cookies
Natural News uses cookies to improve your experience on our site. By using this site, you agree to our privacy policy.
Learn More
Get 100% real, uncensored news delivered straight to your inbox
You can unsubscribe at any time. Your email privacy is completely protected.